<DOC>
	<DOCNO>NCT02226640</DOCNO>
	<brief_summary>This study identify different subtypes type 2 diabetes . The investigator look information molecular level , may lead personalized diagnosis therapy .</brief_summary>
	<brief_title>Uncovering 'ORIGINS ' Diabetes</brief_title>
	<detailed_description>Type 2 diabetes mellitus ( T2DM ) approach epidemic prevalence US adult population ( 1 10 US adult 20 ) . Diabetes diagnose base fast hyperglycemia , oral glucose intolerance marker hyperglycemia HbA1c . However , recognize diabetes heterogeneous disorder . With exist overly simplistic diagnostic criterion , treatment failure rate high virtually every agent currently drug arsenal - include insulin . In late 1990 's oncologist pioneer use high-throughput molecular technology , transcriptome profiling recently metabolomics identify discrete sub-classes cancer distinguish histologically small number biochemical marker . That effort rapidly accelerate pace scientific discovery quickly lead development personalize cancer therapeutic . We believe cancer effort provide roadmap biomarker discovery personalize therapy diabetes . molecular phenotyping ( profile metabolome , transcriptome , epigenome ) advance bioinformatics analysis identify discrete subtypes diabetes - usher new era personalize diagnosis therapy diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Age &gt; 18 HbA1C &lt; 8.0 % * You gain lose 3 kg 6.6 pound last 8 week You lose 10 % heavy body weight lifetime BMI &lt; 25 kg/m2 &gt; 30 kg/m2 Women : 1 year postpartum Have diabetes able maintain accurate reliable home glucose monitor log Treatment 2 follow : metformin ( Fortamet , Glucophage , Glumetza , Riomet ) , sulfonylurea ( Glucotrol , Diabeta , Glynase , Micronase ) , Glucagonlike peptide1 analog ( Byetta ) and/or Dipeptidyl peptidase IV inhibitor ( Januvia , Onglyza ) Treatment long act Glucagonlike peptide1 agonist within last 3 month ( i.e . exenatide weekly ) Treatment thiazolidinediones ( TZDs ) ( i.e . Avandia , Actos , Rezulin ) within last 3 month Known , untreated thyroid disease abnormal thyroid function blood test . * Known diagnosis liver disease ( except NASH ) elevate liver function blood test Known diagnosis kidney disease elevate kidney function blood test Uncontrolled high blood pressure ( BP &gt; 140 systolic &gt; 90 diastolic ) Start change oral contraceptive hormone replacement therapy within last 3 month Use drug alcohol ( &gt; 3 drink per day ) within last 5 year . Uncontrolled psychiatric disease would interfere study participation . History cancer within last 5 year ( skin cancer , exception melanoma , may acceptable ) History organ transplant History heart attack within last 6 month Current treatment blood thinner antiplatelet medication safely stop test procedure Current anemia History HIV , active Hepatitis B C , Tuberculosis Presence clinically significant abnormality electrocardiogram . Current smoker ( smoke nicotine nonnicotine product within past 3 month ) Use medication know influence glucose , fat and/or energy metabolism within last 3 month ( e.g. , growth hormone therapy , glucocorticoid [ steroid ] , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>